rope01 rope02

News

Media Contact
Jim Mazzola
Turning Point Therapeutics
jim.mazzola@tptherapeutics.com
858-925-7984

Press Releases

Publications & Posters

April 2019
AACR 2019: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

April 2019
AACR 2019: Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations

April 2019
AACR 2019: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling

April 2019
AACR 2019:TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses

September 2018
WCLC 2018: Safety and Preliminary Clinical Activity of Repotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer

August 2018
Cancer Discovery: Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations

June 2018
ASCO 2018: A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor repotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).

June 2014
Journal of Medicinal Chemistry: Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress

March 2014
ACS Medicinal Chemistry Letters: A new challenging and promising era of tyrosine kinase inhibitors

September 2011
Journal of Medicinal Chemistry: Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

ltBlueRP03 ltBlueRP02left ltBlueRP02left

Terms of Use | Copyright © 2019 Turning Point Therapeutics, Inc. | All Rights Reserved